You just read:

AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease

News provided by

AgeneBio

Jan 17, 2019, 08:00 ET